Skip to main content
SpringerLink
Log in

Bromocriptine and Related Compounds for Ovulation Induction in Hyperprolactinemia

  • Chapter
Ovulation Induction

Part of the book series: Clinical Perspectives in Obstetrics and Gynecology ((CPOG))

  • 110 Accesses

Abstract

In order to understand the treatment of hyperprolactinemia, it is helpful to know the causes of hyperprolactinemia and its effects on fertility. To this end, the normal regulation of pituitary secretion of prolactin is reviewed, along with alterations of the normal physiology by disease or drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Suh HK, Frantz AG. Size heterogeneity of human prolactin in plasma and pituitary extracts. J Clin Endocrinol Metab. 1974; 39: 928–35.

    Article  PubMed  CAS  Google Scholar 

  2. Makoff E, Lee DW. Glycosylated prolactin is a major circulating variant in human serum. J Clin Endocrinol Metab. 1987; 65: 1102–06.

    Article  Google Scholar 

  3. Niall HD. The chemistry of prolactin. In: Jaffe RB, ed. Prolactin. New York: Elsevier/ North Holland, 1981: 1–18.

    Google Scholar 

  4. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big-big prolactin. J Clin Endocrinol Metab. 1981; 53: 863–66.

    Article  PubMed  CAS  Google Scholar 

  5. Maurer RA. Estradiol regulates transcription of the prolactin gene. J Biol Chem. 1982; 157: 2133–36.

    Google Scholar 

  6. Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocr Rev. 1985; 6: 564–89.

    Article  PubMed  CAS  Google Scholar 

  7. Leong DA, Frawley LS, Neill JD. Neuroendocrine control of prolactin secretion. Ann Rev Physiol. 1983; 45: 109–27.

    Article  CAS  Google Scholar 

  8. Martin MC, Weiner RI, Monroe SE, et al. Prolactin-secreting adenomas in women VII. Dopamine regulation of prolactin secretion. J Clin Endocrinol Metab. 1984; 59: 485–90.

    Article  PubMed  CAS  Google Scholar 

  9. del Pozo E, Brownell J. Prolactin: I. mechanism of control. Horm Res. 1979; 10: 143–72.

    Article  PubMed  Google Scholar 

  10. Lamberts SWJ, Verleun T, Hofland L et al. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. J Clin Endocrinol Metab. 1986; 63: 1342–47.

    Article  PubMed  CAS  Google Scholar 

  11. Nickolics K, Mason A J, Szenyi E, et al. A prolactin-inhibiting factor within the precursor for human gonadotropin releasing hormone. Nature. 1985; 316: 511–17.

    Article  Google Scholar 

  12. Frantz AG. Prolactin. N Engl J Med. 1978; 198: 201–07.

    Article  Google Scholar 

  13. Weitzman E, Boyar RM, Kaper S, et al. The relationship of’sleep and sleep stages to neuroendocrine secretion and biological rhythms in man. Recent Prog Horm Res. 1975; 31: 399–446.

    PubMed  CAS  Google Scholar 

  14. Klibanski A, Beitins IZ, Merriam GR, et al. Gonadotropin and prolactin pulsations in hy-perprolactinemic women before and during bromocriptine therapy. J Clin Endocrinol Metab. 1984; 58: 1141–46.

    Article  PubMed  CAS  Google Scholar 

  15. Cronin MJ, Cheung CY, Wilson CB, et al. [3H] Spiperone binding to human anterior pi-tuitaries and pituitary adenomas secreting prolactin, growth hormone and adrenocorticotropic hormone. J Clin Endocrinol Metab. 1980; 50: 387–91.

    Article  PubMed  CAS  Google Scholar 

  16. Quigley ME, Judd SJ, Gilliland GB, et al. Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenomas. J Clin Endocrinol Metab. 1980; 50: 994–98.

    Article  PubMed  CAS  Google Scholar 

  17. Crosignani PG, Reschini E, Peracchi M, et al. Failure of dopamine infusion to suppress the plasma prolactin response to sulpuride in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab. 1977; 45: 841–44.

    Article  PubMed  CAS  Google Scholar 

  18. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977; 296: 589–600.

    Article  PubMed  CAS  Google Scholar 

  19. Conenblum B, Sirek AMT, Horvath E, et al. Human mixed somatotrophic and lactotroph-ic pituitary adenomas. J Clin Endocrinol Metab. 1976; 42: 857–63.

    Article  Google Scholar 

  20. Hoffman WH, Gala RR, Kovacs K, et al. Ectopic prolactin secretion from a gonadoblasto-ma. Cancer. 1987; 60: 2690–95.

    Article  PubMed  CAS  Google Scholar 

  21. Rees IH, Bloomfield GA, Rees GM, et al. Mut-iple hormones in a bronchial tumor. J Clin Endocrinol Metab. 1974; 38: 1090–93.

    Article  PubMed  CAS  Google Scholar 

  22. Corenblum B, Taylor PJ. Idiopathic hyperprolactinemia may include a distinct entity with a natural history different from that of prolactin adenomas. Fertil Steril. 1988; 49: 455–546.

    Google Scholar 

  23. Martin TL, Kim M, Markey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab. 1985; 60: 855–58.

    Article  PubMed  CAS  Google Scholar 

  24. Burrow GN, Wortzman G, Newcastle NB, et al. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981; 304: 156–58.

    Article  PubMed  CAS  Google Scholar 

  25. March CM, Kletzky OA, Davajan V, et al. Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol. 1981; 139: 835–41.

    PubMed  CAS  Google Scholar 

  26. Wiebe RH, Hammond CB, Borchert LG. Diagnosis of prolactin secreting microadenoma. Am J Obstet Gynecol. 1976; 126: 993–96.

    PubMed  CAS  Google Scholar 

  27. Turksoy RN, Fairber M, Mitzhell GW. Diagnostic and therapeutic modalities in women with galactorrhea. Obstet Gynecol. 1980; 56: 323–28.

    PubMed  CAS  Google Scholar 

  28. Shoupe D, Lobo RA. Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome. Fertil Steril. 1985; 43: 549–53.

    PubMed  CAS  Google Scholar 

  29. Lunde O. Hyperprolactinemia in polycystic ovary syndrome. Ann Chir Gynaecol 1981; 70: 197–201.

    PubMed  CAS  Google Scholar 

  30. Luciano AA, Chapler FK, Sherman BM. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril. 1984; 41: 719–25.

    PubMed  CAS  Google Scholar 

  31. Futterweit W, Krieger DT. Pituitary tumors associated with hyperprolactinemia and PCO disease. Fertil Steril. 1979; 31: 608–13.

    PubMed  CAS  Google Scholar 

  32. Alger M, Vasquez-Matute L, Mason M, et al. PCOD associated with hyperprolactinemia and defective metoclopramide response. Fertil Steril. 1980; 34: 70–71.

    PubMed  CAS  Google Scholar 

  33. Quigley ME, Rakoff JS, Yen, SSC. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab. 1981; 52: 231–34.

    Article  PubMed  CAS  Google Scholar 

  34. Blum I, Bruhis S, Kaufman H. Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone. Fertil Steril. 1981; 35: 629–33.

    PubMed  CAS  Google Scholar 

  35. Buvat J, Buvat-Herbant M, Marcolin G, et al. Acute effects of bromocriptine on gonadotropin secretion in PCO. Fertil Steril. 1985; 44: 356–60.

    PubMed  CAS  Google Scholar 

  36. Silverman AY, Schwartz SL, Steger RW. A quantitative difference between immunologically and biologically active prolactin in hy-pothyroid patients. J Clin Endocrinol Metab. 1982; 55: 272–75.

    Article  PubMed  CAS  Google Scholar 

  37. Keye WR, Yuen BH, Knopf RF, et al. Amenorrhea, hyperprolactinemia and pituitary secondary to primary hypothyroidism. Obstet Gynecol. 1976; 48: 697–702.

    PubMed  CAS  Google Scholar 

  38. Cooper DS, Ridgway EC, Kliman B, et al. Metabolic clearance and production rates of prolactin in man. J Clin Invest. 1979; 64: 1669–80.

    Article  PubMed  CAS  Google Scholar 

  39. Sievertsen GD, Lim VS, Nakawatase C, et al. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980; 50: 846–50.

    Article  PubMed  CAS  Google Scholar 

  40. Van Thiel DH, McClain CJ, Elson MK, et al. Evidence for autonomous secretion of prolactin in some alcoholic men with cirrhosis and gynecomastia. Metabolism. 1978; 27: 1778–84.

    Article  PubMed  Google Scholar 

  41. Monroe SE, Levine L, Keye WR, et al. Prolactin secreting pituitary adenomas in women V. Increased gonadotrope sensitivity in hyperprolactinemic women with pituitary adenomata. J Clin Endocrinol Metb. 1981; 52: 1171–78.

    Article  CAS  Google Scholar 

  42. Kauppilla A, Leinonen P, Vihko P, et al. Meto-clopromide-induced hyperprolactinemia impairs follicle maturation and corpus luteum function in women. J Clin Endocrinol Metab. 1982; 54: 955–60.

    Article  Google Scholar 

  43. Reinthaller A, Bieglmayer C, Deutinger C, et al. Transient hyperprolactinemia during cycle stimulation: influence on the endocrine response and fertilization rate of human oocytes and effects of bromocriptine treatment. Fertil Steril. 1988; 49: 432–36.

    PubMed  CAS  Google Scholar 

  44. Cutie ER, Andino NA. Prolactin inhibits the steroidogenesis in midfollicular phase human granulosa cells cultured in a chemically defined medium. Fertil Steril. 1988; 49: 632–37.

    PubMed  CAS  Google Scholar 

  45. del Pozo E, Wyss H, Tolis G, et al. Prolactin and deficient luteal function. Obstet Gynecol. 1979; 53: 282–85.

    PubMed  Google Scholar 

  46. Saunders DM, Hunter JC, Haase HR, et al. Treatment of luteal phase inadequacy with bromocriptine. Obstet Gynecol. 1979; 53: 287–89.

    PubMed  CAS  Google Scholar 

  47. Pepperell RJ. Prolactin and reproduction. Fertil Steril. 1981; 35: 267–74.

    PubMed  CAS  Google Scholar 

  48. Vanrell JA, Balasch J. Prolactin in the evaluation of luteal phase in infertility. Fertil Steril. 1983; 39: 30–33.

    PubMed  CAS  Google Scholar 

  49. Kauppila A, Martikainen H, Puistola U, et al. Hypoprolactinemia and ovarian function. Fertil Steril. 1988; 49: 437–41.

    PubMed  CAS  Google Scholar 

  50. Schulz KD, Gerger W, del Pozo E, et al. Pattern of sexual steroids, prolactin and gonadotropic hormones during prolactin inhibition in normally cycling women. Am J Obstet Gynecol. 1978; 132: 561–66.

    PubMed  CAS  Google Scholar 

  51. Wallace A, Lees DAR, Roberts ADG et al. Danazol and prolactin status in patients with endometriosis. Acta Endocrinola. 1984; 107: 445–49.

    CAS  Google Scholar 

  52. Bahamondes L, Saboya W, Tramascia M, et al. Galactorrhea, infertility and short luteal phases in hyperprolactinemic women: early stage of amenorrhea-galactorrhea? Fertil Steril. 1979; 32: 476–77.

    PubMed  CAS  Google Scholar 

  53. Sadeghi-Nejad A, Wolfdorf JI, Biller B, et al. Brief clinical and laboratory observations: hyperprolactinemia causing primary amenorrhea. J Pediatr. 1981; 99: 592–93.

    Google Scholar 

  54. Ferrari C, Telloli P, Rampini P, et al. Hyperprolactinemic primary amenorrhea. Gynecol Obstet Invest. 1980; 11: 317–26.

    Article  Google Scholar 

  55. Keye WR, Chang RJ, Wilson CB, et al. Pro-lactin-secreting adenomas. III. Frequency and diagnosis in amenorrhea galactorrhea. JAMA. 1980; 244: 1329–32.

    Article  PubMed  Google Scholar 

  56. Bohnet HG, Dahlen HG, Wuttke W, et al. Hyperprolactinemic anovulatory syndrome. J Clin Endocrinol Metab. 1975; 42: 132–43.

    Article  Google Scholar 

  57. Barnes AB. Diagnosis and treatment of abnormal breast conditions. N Engl J Med. 1966; 275: 1184–87.

    Article  PubMed  CAS  Google Scholar 

  58. MacFarlane I A, Rosen MD. Galactorrhea following surgical procedures to the chest wall: the role of prolactin. Postgrad Med J. 1980; 56: 23–25.

    Article  PubMed  CAS  Google Scholar 

  59. Noel GL, Sutt HK, Stone JG, et al. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab. 1972; 35: 840–51.

    Article  PubMed  CAS  Google Scholar 

  60. Tolis G, Somma M, Van Casppenhout J, et al. Prolactin secretion in 65 patients with galactorrhea. Am J Obstet Gynecol. 1974; 118: 91–101.

    PubMed  CAS  Google Scholar 

  61. Sarkar DK, Yen SSC. Hyperprolactinemia decreases the LHRH concentration in pituitary portal plasma, a possible role for β-endorphin as a mediator. Endocrinology. 1985; 116: 2080–84.

    Article  PubMed  CAS  Google Scholar 

  62. Higuchi K, Nawata H, Maki T, et al. Prolactin has a direct effect on adrenal androgen secretion. J Clin Endocrinol Metab. 1984; 59: 714–18.

    Article  PubMed  CAS  Google Scholar 

  63. Keye W, Chang J, Wilson C, et al. Prolactin-secreting pituitary adenomas. JAMA. 1980; 244: 1329–32.

    Article  PubMed  Google Scholar 

  64. Chang RJ, Keye W, Monroe S, et al. Pro-lactin-secreting pituitary adenomas in women IV. Pituitary function in amenorrhea associated with normal or abnormal serum prolactin and sellar polytomography. J Clin Endocrinol Metab. 1980; 51: 830–35.

    Article  PubMed  CAS  Google Scholar 

  65. Quigley ME, Judd SJ, Gilliland GB, et al. Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactine-mic anovulation. J Clin Endocrinol Metab. 1979; 48: 718–720.

    Article  PubMed  CAS  Google Scholar 

  66. Quigley ME, Sheehan KL, Casper RF, et al. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotrophic amenorrhea. J Clin Endocrinol Metab. 1980; 50: 949–54.

    Article  PubMed  CAS  Google Scholar 

  67. Suginami H, Hamada K, Yano K, et al. Ovulation induction with bromocriptine in normo-prolactinemic anovulatory women. J Clin Endocrinol Metab. 1986; 62: 899–902.

    Article  PubMed  CAS  Google Scholar 

  68. Corenblum B, Taylor PJ. A rationale for the use of bromocriptine in patients with amenorrhea and normoprolactinemia. Fertil Steril. 1980; 34: 239–42.

    PubMed  CAS  Google Scholar 

  69. Peillon F, Vincens M, Cesselin F, et al. Exaggerated prolactin response of TRH in women with anovulatory cycles: possible role of endogenous estrogens and effect of bromocriptine. Fertil Steril. 1982; 37: 530–33.

    PubMed  CAS  Google Scholar 

  70. Bruneton JN, Drovillard JP, Sabatier JC, et al. Normal variants of the sella turcica. Radiology. 1979; 131: 99–104.

    PubMed  CAS  Google Scholar 

  71. Muhr G, Bergstrom K, Grimelias L, et al. A parallel study of roentgen anatomy of the sella turcica and the histopathology of the pituitary gland in 205 autopsy specimens. Neuroradiology. 1981; 21: 55–65.

    Article  PubMed  CAS  Google Scholar 

  72. Kendall B. Current approaches to hypothalamic pituitary radiology. Clin Endocrinol Metab. 1983; 12: 353–66.

    Article  Google Scholar 

  73. Ghigo E, Ciccarellie, Bianchi SD, et al. Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinemia. Acta Endocrinol. 1986; 112: 20–27.

    PubMed  CAS  Google Scholar 

  74. Hankins CA, Zamini AA, Rumbaugh CL. Prolactinomas, clinical presentation radiologic assessment and therapeutic options. Invest Radiol. 1985; 20: 345–54.

    Article  PubMed  CAS  Google Scholar 

  75. Wolpert SM, Molitch ME, Goldman JA, et al. Size, shape and appearance of the normal female pituitary gland. Am J Neuro Rad. 1984; 5: 263–67.

    Google Scholar 

  76. Schwartz JD, Russel KB, Basile BA, et al. High resolution computed tomographic appearance of the intrasellar contents in women of child-bearing age. Radiology. 1983; 147: 115–17.

    Google Scholar 

  77. Ropollo H, Atchaw R, Meyer J, et al. Normal pituitary gland: 1. Macroscopic anatomy— CT correlation. Am J Neurorad. 1983; 4: 927–35.

    Google Scholar 

  78. Davis PC, Hoffman JC, Spencer T, et al. MR imaging of pituitary adenoma: CT, clinical and surgical correlation. Am J Radiol. 1987; 148: 797–802.

    CAS  Google Scholar 

  79. Teasdale E, Teasdale G, Mohsen F, et al. High resolution computed tomography in pituitary microadenoma: is seeing believing? Clin Radiol. 1986; 37: 227–32.

    Article  PubMed  CAS  Google Scholar 

  80. Chambers RE, Turski PA, LaMasters D, et al. Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic process. Radiology. 1982; 144: 109–13.

    PubMed  CAS  Google Scholar 

  81. Taylor CR, Jaffe CC. Methodological problems in clinical radiology research: pituitary microadenoma detection as a pradignm. Radiology. 1983; 147: 279–83.

    PubMed  CAS  Google Scholar 

  82. Kaufman B. Magnetic resonance imaging of the pituitary gland. Radiol Clin North Am. 1984; 22: 795–803.

    PubMed  CAS  Google Scholar 

  83. Kucharczyk W, Davis DO, Kelly WM, et al. Pituitary adenomas: high resolution MR imaging at 1.5T. Radiology. 1986; 161: 761–65.

    PubMed  CAS  Google Scholar 

  84. Glaser B, Sheinfield M, Benmair J, et al. Magnetic resonance imaging of the pituitary gland. Clin Radiol, 1986; 37: 9–14.

    Article  PubMed  CAS  Google Scholar 

  85. Bilaniuk LT, Zimmerman RA, Wehrli FW, et al. Magnetic resonance imaging of pituitary lesions using 1.0 to 1.5 T field strength. Radiology. 1984; 153: 415–18.

    PubMed  CAS  Google Scholar 

  86. Syvertson A, Haughton VM, Williams AL, et al. The computed tomographic appearance of the normal pituitary gland and pituitary microadenomas. Radiology. 1979; 133: 385–91.

    Google Scholar 

  87. Swartz J, Russell K, Basile B. Resolution computed tomographic appearance of the intrasellar contents in women of child bearing age. Radiology. 1983; 147: 115–17.

    PubMed  CAS  Google Scholar 

  88. Muller EE, Panarai AE, Cocchi D, et al. Endocrine profile of ergot alkaloids. Life Sci. 1977; 21: 1545–58.

    Article  PubMed  CAS  Google Scholar 

  89. Vance ML, Evans WS, Thorner MO. Bromocriptine. Ann Intern Med. 1984; 100: 78–91.

    CAS  Google Scholar 

  90. Corrodi H, Fuxe K, Hokfelt T, et al. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol. 1973; 25: 409–12.

    Article  PubMed  CAS  Google Scholar 

  91. Esiri MM, Bevan JS, Burke CW, et al. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab. 1986; 63: 383–88.

    Article  PubMed  CAS  Google Scholar 

  92. Bassetti M, Spada A, Pezzo G, et al. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study. J Clin Endocrinol Metab. 1984; 58: 268–73.

    Article  PubMed  CAS  Google Scholar 

  93. Warfield A, Finkel DM, Schatz NJ, et al. Bromocriptine treatment of prolactin-secret-ing pituitary adenomas may restore pituitary function. Ann Intern Med. 1984; 101: 783–85.

    PubMed  CAS  Google Scholar 

  94. Montini M, Pagani G, Gianola D, et al. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. J Clin Endocrinol Metab. 1986; 63: 266–68.

    Article  PubMed  CAS  Google Scholar 

  95. Vermish M, Fossum GT, Kletzky DA. Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Am J Obstet Gynecol. 1988; 72: 693–98.

    Google Scholar 

  96. Soto-Albors C, Randolph J, Ying YK, et al. Medical management of hyperprolactinemia: a lower dose of bromocriptine may be effective. Fertil Steril. 1987; 48: 213–17.

    PubMed  CAS  Google Scholar 

  97. Ciccarelli E, Mazza E, Ghigo E, et al. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia. J Endocrinol Invest. 1987; 10: 51–53.

    PubMed  CAS  Google Scholar 

  98. Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 1985; 60: 698–705.

    Article  PubMed  CAS  Google Scholar 

  99. Badano AR, Miechi HB, Mirkin A, et al. Bromocriptine in the treatment of hyper-prolactinemic amenorrhea. Fertil Steril. 1979; 31: 124–29.

    PubMed  CAS  Google Scholar 

  100. Molitch ME. Pregnancy and the hyper-prolactinemic woman. N Engl J Med. 1985; 312: 1364–70.

    Article  PubMed  CAS  Google Scholar 

  101. Daughaday WH. The anterior pituitary. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology, Philadelphia: W. B. Saunders. 1985: 568–613.

    Google Scholar 

  102. Thorner MO, Perryman RL, Rogol AD, et al. Rapid changes in prolactinoma volume after withrdrawal of and re-institution of bromocriptine. J Clin Endocrinol Metab. 1981; 53: 480–83.

    Article  PubMed  CAS  Google Scholar 

  103. Crosignani PG, Ferrari C, Liuzzi A, et al. Treatment of hyperprolactinemic states with different drugs: a study of bromocriptine, metergoline and lisuride. Fertil Steril. 1982; 37: 61–67.

    PubMed  CAS  Google Scholar 

  104. Casson IF, Walker BA, Hipkin LJ, et al. Intolerance of bromocriptine: is metergoline a satisfactory alternative? Br Med J. 1985; 290: 1783–84.

    Article  CAS  Google Scholar 

  105. Crosignani PG, Peracchi M, Lombroso GC, et al. Antiserotonin treatment of hyperprolactinemic amenorrhea: long-term follow-up with metergoline, methysergide and cyprokepta-dine. Am J Obstet Gynecol. 1978; 132: 307–12.

    PubMed  CAS  Google Scholar 

  106. Bohnet HG, Kato K, Wolf AS. Treatment of hyperprolactinemic amenorrhea with metergoline. Obstet Gynecol. 1986; 67: 249–52.

    Article  PubMed  CAS  Google Scholar 

  107. Kleinberg DL, Boyd AE, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med. 1983; 309: 704–09.

    Article  PubMed  CAS  Google Scholar 

  108. Blackwell RE, Bradley EL, Kline LB, et al. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study. Fertil Steril. 1983; 39: 744–48.

    PubMed  CAS  Google Scholar 

  109. Grossman A, Bouloux PMG, Loneragan R, et al. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinemia. Clin Endocrinol. 1985; 22: 611–16.

    Article  CAS  Google Scholar 

  110. Stracke H, Heinlein W, Horowski R, et al. Dopamine agonists in the treatment of hyperprolactinemia, comparison between bromocriptine and lisuride. Arzneim Forsch/Drug Res. 1986; 36: 1834–36.

    CAS  Google Scholar 

  111. Liuzzi A, Dallabonzana D, Oppizzi G, et al. Low doses of dopamine agonists in the long term treatment of macroprolactinomas. N Engl J Med. 1985; 313: 656–59.

    Article  PubMed  CAS  Google Scholar 

  112. Bouloux PMG, Besser GM, Moult PJA, et al. Clinical evaluation of lysuride in the management of hyperprolactinemia. Br Med J. 1987; 294: 1323–24.

    Article  CAS  Google Scholar 

  113. Ciccarelli E, Touzel R, Besser M, et al. Terguride—a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil Steril. 1988; 49: 589–94.

    PubMed  CAS  Google Scholar 

  114. Graf KJ, Kohler D, Horowski R, et al. Rapid regression of macroprolactinomas by the new dopamine agonist terguride. Acta Endocrinol. 1986; 111: 460–66.

    PubMed  CAS  Google Scholar 

  115. Dallabonzana D, Liuzzi A, Oppizzi G, et al. Effect of the new ergot derivative on plasma prolactin and GH in patients with pathological hyperprolactinemia or acromegaly. J Endocrinol Invest. 1985; 8: 147–51.

    PubMed  CAS  Google Scholar 

  116. Hesla JS, Rodman EF, Molitch ME, et al. The effect of the ergoline derivative, CU 32–085, on prolactin secretion in hyperprolacti-nemic women. Fertil Steril. 1987; 48: 555–59.

    PubMed  CAS  Google Scholar 

  117. Dewailly D, Thomas P, Buvat J, et al. Treatment of human hyperprolactinemia with a new dopamine agonist: CU32085 (mesulergin). Acta Endocrinol. 1985; 110: 433–39.

    PubMed  CAS  Google Scholar 

  118. Poulsen HK, Rasmussen P, Petersen MR, et al. Puerperal lactation inhibition with a novel 8 alpha aminoergoline (CU32/085). Gynecol Obstet Invest. 1984; 17: 139–44.

    Article  Google Scholar 

  119. Ferrari C, Barbieri C, Caldar E, et al. Long-lasting prolactin-lowering effect of carbergo-line, a new dopamine agonist, in hyperpro-lactinemic patients. J Clin Endocrinol Me-tab. 1986; 63: 941–45.

    Article  CAS  Google Scholar 

  120. Mattei AM, Ferrari C, Baroldi P, et al. Pro-lactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyper-prolactinemic patients. J Clin Endocrinol Metab. 1988; 66: 193–98.

    Article  PubMed  CAS  Google Scholar 

  121. Pontiroli AE, Cammelli L, Baroldi P, et al. Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug. J Clin Endocrinol Metab. 1987; 65: 1057–59.

    Article  PubMed  CAS  Google Scholar 

  122. Melis AB, Gambacciani M, Paoletti AM, et al. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist carbergoline in normal cycling, puerpera, and hyperprolactinemic women. J Clin Endocrinol Metab. 1987; 65: 541–45.

    Article  PubMed  CAS  Google Scholar 

  123. Radwanska E, McGarrigle HHG, Little V, et al. Induction of ovulation in women with hyperprolactinemic amenorrhea using clom-iphene and human chorionic gonadotropin or bromocriptine. Fertil Steril. 1979; 32: 187–92.

    PubMed  CAS  Google Scholar 

  124. Farine D, Dor J, Lupo vici N, et al. Conception rate after gonadotropin therapy in hyperprolactinemia and normoprolactinemia. Obstet Gynecol. 1985; 65: 658–60.

    PubMed  CAS  Google Scholar 

  125. Archer DF, Josimovich JB. Ovarian responses to exogenous gonadotropins in women with elevated serum prolactin. Obstet Gynecol. 1976; 48: 155–57.

    PubMed  CAS  Google Scholar 

  126. Jansen RPS, Handelsman DJ, Boylan LM, et al. Pulsatile intravenous gonadotropin-releasing hormone for ovulation-induction in infertile women. I. safety and effectiveness with outpatient therapy. Fertil Steril. 1987; 48: 33–38.

    PubMed  CAS  Google Scholar 

  127. Gindoff PR, Loucapoulos A, Jewelewicz R. Treatment of hyperprolactinemic amenorrhea with pulsatile gonadotropin releasing hormone. Fertil Steril. 1986; 46: 1156–58.

    PubMed  CAS  Google Scholar 

  128. Chang RJ, Keye WR, Young JR, et al. Detection, evaluation and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea. Am J Obstet Gynecol. 1977; 128: 356–63.

    PubMed  CAS  Google Scholar 

  129. Kletzky OA, Kawajan V. Hyperprolactinemia. In: Mishell DR, Davajan V, eds. Infertility, contraception and reproductive endocrinology. New Jersey: Medical Economics, 1986: 275–99.

    Google Scholar 

  130. Schlechte JA, Sherman BM, Chapler FK, et al. Long term follow-up of women with surgically treated prolactin secreting pituitary tumors. J Clin Endocrinol Metab. 1986; 62: 1296–1301.

    Article  PubMed  CAS  Google Scholar 

  131. Serri O, Rasio E, Beaugard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med. 1983; 309: 280–83.

    Article  PubMed  CAS  Google Scholar 

  132. Horvath E, Kovacs K, Smyth AS, et al. A novel type of pituitary adenoma: morphological features and clinical correlation. J Clin Endocrinol Metab. 1988; 66: 1111–18.

    Article  PubMed  CAS  Google Scholar 

  133. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril. 1979; 31: 363–72.

    PubMed  CAS  Google Scholar 

  134. Divers WA, Yen SSC. Prolactin producing microadenomas in pregnancy. Obstet Gynecol. 1983; 62: 425–29.

    PubMed  Google Scholar 

  135. Daya S, Shewchuk AB, Bryeland N. The effect of multiparity on intra-sellar prolactinomas. Am J Obstet Gynecol. 1984; 148: 512–15.

    PubMed  CAS  Google Scholar 

  136. Rasmussen C, Bergh T, Nillius S, et al. Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. Fertil Steril. 1985; 44: 31–34.

    PubMed  CAS  Google Scholar 

  137. Samaah N, Leavens ME, Sacca R, et al. The effects of pregnancy on patients with hyperprolactinemia. Am J Obstet Gynecol. 1984; 148: 466–73.

    Google Scholar 

  138. Crosignani PG, Ferrari C, Scarduelli C, et al. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol. 1981; 58: 708–13.

    PubMed  CAS  Google Scholar 

  139. Crosignani PG, Matteir AM, Cavioni V. Is pregnancy the best permanent cure for hyper-prolactinemia? Paper presented at the conjoint annual meeting of the American Fertility Society and the Canadian Fertility and Andrology Society, 1986.

    Google Scholar 

  140. Rjosk HK, Fahlbusch R, von Werder K. Influence of pregnancies on prolactinomas. Acta Endrocinol. 1982; 100: 337–46.

    CAS  Google Scholar 

  141. Andersen AN, Starup J, Tabor A, et al. The possible prognostic value of serum prolactin increment during pregnancy in hyperprolactinemic patients. Acta Endocrinol. 1983; 102: 1–5.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Vivian Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna K. Parsons
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Reproductive Endocrinology and Infertility/A81, Department of Gynecology, The Cleveland Clinic Foundation, 44195-5037, Cleveland, Ohio, USA

    Robert L. Collins M.D. (Director of Education) (Director of Education)

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Lewis, V., Parsons, A.K. (1991). Bromocriptine and Related Compounds for Ovulation Induction in Hyperprolactinemia. In: Collins, R.L. (eds) Ovulation Induction. Clinical Perspectives in Obstetrics and Gynecology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3026-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-3026-7_9

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7766-8

  • Online ISBN: 978-1-4612-3026-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation